Back to User profile » Mr Alan Hamilton
Papers published by Mr Alan Hamilton:
Three-minute constant rate step test for detecting exertional dyspnea relief after bronchodilation in COPD
Borel B, Wilkinson-Maitland CA, Hamilton A, Bourbeau J, Perrault H, Jensen D, Maltais F
International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:2991-3000
Published Date: 29 November 2016
Pharmacokinetics and safety of olodaterol administered with the Respimat Soft Mist inhaler in subjects with impaired hepatic or renal function
Kunz C, Luedtke D, Unseld A, Hamilton A, Halabi A, Wein M, Formella S
International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:585-595
Published Date: 18 March 2016
The lung function profile of once-daily tiotropium and olodaterol via Respimat® is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler® (ENERGITO® study)
Beeh KM, Derom E, Echave-Sustaeta J, Grönke L, Hamilton A, Zhai D, Bjermer L
International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:193-205
Published Date: 3 February 2016
Efficacy and safety of the long-acting β2-agonist olodaterol over 4 weeks in Japanese patients with chronic obstructive pulmonary disease
Ichinose M, Takizawa A, Izumoto T, Tadayasu Y, Hamilton AL, Kunz C, Fukuchi Y
International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:1673-1683
Published Date: 20 August 2015
Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol
Roskell NS, Anzueto A, Hamilton A, Disse B, Becker K
International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:813-824
Published Date: 31 July 2014
Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2–4 COPD: results from two replicate 48-week studies
Koch A, Pizzichini E, Hamilton A, Hart L, Korducki L, De Salvo MC, Paggiaro P
International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:697-714
Published Date: 5 July 2014
Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2–4 COPD: results from two replicate 48-week studies
Ferguson GT, Feldman GJ, Hofbauer P, Hamilton A, Allen L, Korducki L, Sachs P
International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:629-645
Published Date: 16 June 2014
Assessing patient report of function: content validity of the Functional Performance Inventory-Short Form (FPI-SF) in patients with chronic obstructive pulmonary disease (COPD)
Leidy NK, Hamilton A, Becker K
International Journal of Chronic Obstructive Pulmonary Disease 2012, 7:543-554
Published Date: 30 August 2012